百令胶囊辅助治疗慢性阻塞性肺疾病患者的免疫生物标记物水平变化分析  

Analysis of the changes of immune biomarkers in patients with chronic obstructive pulmonary disease treated with Bailing Capsules

作　　者：黄惠敏[1] 胡海圣 蔡传旭 郑佩燕[1] 方艳婷 孙宝清[1] HANG Huimin;HU Haisheng;CAI Chuanxu;ZHENG Peiyan;FANG Yanting;SUN Baoqing(Department of Clinical Laboratory,National Center for Respiratory Medicine,National Clinical Research Center for Respiratory Disease,State Key Laboratory of Respiratory Disease,Guangzhou Institute of Respiratory Health,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Department of Laboratory Medicine,Shenzhen People's Hospital,Shenzhen 518020,China)

机构地区：[1]广州医科大学附属第一医院检验科,国家呼吸医学中心,国家呼吸系统疾病临床医学研究中心,广州呼吸健康研究院,呼吸疾病国家重点实验室,广州510120 [2]深圳人民医院检验科,深圳518020

出　　处：《广州医科大学学报》2023年第3期43-49,共7页Academic Journal of Guangzhou Medical University

基　　金：广州市中医药和中西医结合科技项目(20202A011017)。

摘　　要：目的:观察长期应用百令胶囊治疗稳定期的中重度慢性阻塞性肺疾病(COPD)患者,监测免疫学指标水平的变化,评价百令胶囊对COPD患者的免疫功能改善情况。方法:双盲平行对照试验,随机入组COPD稳定期中重度患者,并分为试验组和对照组。检测患者治疗前后血液免疫学指标,包括:基质金属蛋白酶8(MMP8)、基质金属蛋白酶9(MMP9)、表面活性物质蛋白-D(SPD)、去甲肾上腺素肾(NE)、白三烯B4(LTB4)、血清淀粉样蛋白A(SAA)、蛋白聚糖4(PRG4)、粒细胞-巨噬细胞集落刺激因子(GM-CSF)、白介素1β(IL-1β)、白介素4(IL-4)、白介素6(IL-6)和白介素8(IL-8)。结果:治疗前,试验组与对照组间MMP8、MMP9、SPD、NE、LTB4和SAA水平没有统计学差异(P>0.05),但对照组的PRG4水平高于试验组(P<0.05);治疗后,试验组与对照组间MMP8、MMP9、NE、LTB4、PRG4和SAA水平均没有统计学差异(P>0.05),但试验组SPD水平高于对照组(P<0.05)。与治疗前相比,试验组的MMP8[717.5(433.6,1366.1)ng/ml VS.384.2(198.3,717.5)ng/ml]和SAA[90.1(56.7,132.4)ng/ml VS.45.1(38.6,57.1)ng/ml]水平均有所下降,差异有统计学意义(Z=-3.428,P<0.05和Z=17.305,P<0.05)。治疗前及治疗后,试验组与对照组间GM-CSF、IL-1β、IL-4、IL-6和IL-8水平均没有统计学差异(P>0.05),但试验组和对照组的IL-8水平在治疗后均有所下降,差异有统计学意义(Z=-4.612,P=0.000和Z=-3.027,P=0.002)。结论:百令胶囊辅助治疗能调节COPD患者免疫生物标记物水平,在一定程度上减轻COPD患者气道炎症。Objective:To observe the long-term application of Bailing Capsules in the treatment of patients with moderate to severe chronic obstructive pulmonary disease(COPD)in the stable stage,monitor the changes in the levels of immunological indicators,and evaluate the improvement of the immune function of Bailing Capsules in COPD patients.Methods:In a double-blind parallel controlled trial,patients with moderate to severe COPD in the stable stage were randomly enrolled and divided into an experimental group and a control group.Detection of blood immunological indicators of patients before and after treatment,including:matrix metalloproteinase 8(MMP8),matrix D0I:10.3969/j.issn.2095-9664.2023.03.08 metalloproteinase 9(MMP9),surfactant protein-D(SPD),norepinephrine(NE),leukotrienes B4(LTB4),serum amyloid A(SAA),proteoglycan 4(PRG4),granulocyte-macrophage colony stimulating factor(GM-CSF),interleukin 1β(IL-1β),interleukin 4(IL-4),interleukin 6(IL-6)and interleukin 8(IL-8).Results:Before treatment,there were no statistically significant differences in the levels of MMP8,MMP9,SPD,NE,LTB4,and SAA between the experimental and control groups(P>0.05).However,the PRG4 level in the control group was higher than that in the experimental group(P<0.05).After treatment,there were no statistically significant differences in the levels of MMP8,MMP9,NE,LTB4,PRG4,and SAA levels between the experimental and control groups(P>0.05).However,the SPD level in the experimental group was higher than that in the control group(P<0.05).Compared to before treatment,the experimental group showed a decrease in MMP8[717.5(433.6,1366.1)ng/ml vs 384.2(198.3,717.5)ng/ml]and SAA[90.1(56.7,132.4)ng/ml vs 45.1(38.6,57.1)ng/ml],with statistically significant differences(Z=-3.428,P<0.05 and Z=17.305,P<0.05).Before and after treatment,there were no statistically significant differences in GM-CSF,IL-1β,IL-4,IL-6,and IL-8 levels between the experimental and control groups(P>0.05).However,the IL-8 level in both the experimental and control groups decreased after

关 键 词：慢性阻塞性肺疾病 百令胶囊 生物标记物 气道炎症 

分 类 号：R563[医药卫生—呼吸系统]